Graft-vs-Host Disease (GVHD)

The group showed that their 14-day model using an easily measurable calculation was able to predict long-term mortality as well as the traditional model using responses from 2 weeks later.

Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).

After years of dependence on systemic corticosteroids, ruxolitinib treatment was effective for an adolescent patient with graft-versus-host disease (GVHD) who was initially thought to have eosinophilic gastroenteritis.